+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Bevacizumab"

Metastatic Colorectal Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Colorectal Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 280 Pages
  • Global
From
Bevacizumab - Biosimilar Insight, 2025 - Product Thumbnail Image

Bevacizumab - Biosimilar Insight, 2025

  • Report
  • April 2025
  • 80 Pages
  • Global
From
Malignant Pleural Mesothelioma- Pipeline Insight, 2025 - Product Thumbnail Image

Malignant Pleural Mesothelioma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hepatic Tumor - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatic Tumor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Vestibular Schwannoma - Pipeline Insight, 2025 - Product Thumbnail Image

Vestibular Schwannoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Regorafenib Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Regorafenib Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
AVASTIN Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

AVASTIN Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
Olaparib + bevacizumab Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Olaparib + bevacizumab Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
From
Ovarian Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Ovarian Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Gastric Neuroendocrine Tumors Pipeline Analysis Report 2025 - Product Thumbnail Image

Gastric Neuroendocrine Tumors Pipeline Analysis Report 2025

  • Report
  • June 2025
  • 200 Pages
  • Global
From
Colorectal Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Colorectal Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Hepatocellular Carcinoma Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Hepatocellular Carcinoma Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
Colorectal Cancer Market Report and Forecast 2025-2034 - Product Thumbnail Image

Colorectal Cancer Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
Colorectal Cancer (CRC) Pipeline Analysis Report - Product Thumbnail Image

Colorectal Cancer (CRC) Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Ovarian Cancer Pipeline Analysis Report - Product Thumbnail Image

Ovarian Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Loading Indicator

Bevacizumab is a monoclonal antibody used in the treatment of various types of cancer. It is used in combination with other drugs to treat metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and metastatic breast cancer. Bevacizumab works by inhibiting the growth of new blood vessels, which can help slow the growth of tumors. It is administered intravenously and is typically given in combination with other chemotherapy drugs. Bevacizumab is a widely used drug in the oncology market, and is one of the most prescribed drugs for cancer treatment. It is used in combination with other drugs to treat a variety of cancers, and is often used in combination with chemotherapy. Bevacizumab has been shown to be effective in treating certain types of cancer, and is generally well tolerated. Some companies in the Bevacizumab market include Genentech, Roche, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more